- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
Sotera Health
Market Cap: US$3.0b
Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$10.51
7D
2.7%
1Y
-4.5%
Repligen
Market Cap: US$6.9b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$122.86
7D
5.8%
1Y
-26.2%
Eli Lilly
Market Cap: US$657.7b
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
LLY
US$732.41
7D
1.2%
1Y
-2.4%
Vertex Pharmaceuticals
Market Cap: US$124.3b
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
VRTX
US$484.22
7D
2.0%
1Y
21.9%
Bruker
Market Cap: US$5.9b
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
BRKR
US$38.76
7D
6.3%
1Y
-55.7%
Natera
Market Cap: US$20.0b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$148.04
7D
7.1%
1Y
63.7%
Niagen Bioscience
Market Cap: US$462.1m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$5.93
7D
5.5%
1Y
50.9%